The store will not work correctly when cookies are disabled.
Cookie Policy:This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Potent platinum-based antineoplastic agent. Analog of cisplatin (Prod. No. AG-CR1-3590) with reduced nephrotoxicity and higher stability.
Antitumor agent.
Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death.
Interferes with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair is impossible.
Apoptosis inducer.
Enhances radiation-induced single-strand DNA breakage.
Chk2 inhibition with carboplatin selectively kills Wwox-deficient cells
Product References
Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function: S.J. Harland, et al.; Cancer Res. 44, 1693 (1984)
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer: I.E. Smith, et al.; Cancer Treat Rep. 69, 43 (1985)
Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer: I.E. Smith & B.D. Evans; Cancer Treat Rev. 12 (Suppl. A), 73 (1985)
Carboplatin enhances the production and persistence of radiation-induced DNA single-strand breaks: L.X. Yang, et al.; Radiation Res. 143, 302 (1995)
Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum (II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited: G. Natarajan, et al.; Biochem. Pharmacol. 58, 1625 (1999)
Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin: O. Heudi, et al.; Biopharm. Drug Dispos. 20, 107 (1999)
What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? J. Lokich; Cancer Invest. 19, 756 (2001)
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA: J. Reedijk; PNAS 100, 3611 (2003)
High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity: J.P. Thomas, et al.; Mol. Pharmacol. 70, 23 (2006)
p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: A novel target of p53 in apoptosis: S. Singh, et al.; FEBS Lett. 581, 289 (2007)
Inhibition of transcription by platinum antitumor compounds: R.C. Todd & S.J. Lippard; Metallomics 1, 280 (2009)
Application of electric cell-substrate impedance sensing toward personalized anti-cancer therapeutic selection: A.F. Adcock, et al.; J. Analyt. Sci. Tec. 9, 17 (2018)
Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells: M.S. Chesnokov, et al.; Cell Death Dis. 12, 704 (2021)
Interaction of Wwox with Brca1 and associated complex proteins prevents premature resection at double-strand breaks and aberrant homologous recombination: D. Park, et al.; DNA Rep. in press (2021)
Download PDF 
